A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Ministry of Health and Welfare Department of Chinese Medicine and pharmacy specially
subsidizes domestic teaching hospitals to install clinical study centers for Chinese
pharmacies, in order to establish the clinical study environment for Chinese pharmacies
meeting the international regulations, to assist promoting and performing clinical studies in
Chinese pharmacies, and then to improve the nation's health and benefits. This will render
Chinese pharmacies competitive in the international market by employing scientific tests and
verifications. The new project applications are respectively as follows: A randomized double
blind placebo control study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) in patients with irritable
bowel syndrome The main clinical manifestations of irritable bowel syndrome (IBS) are
chronic, recurrent abdominal pain or abdominal dyscomfortable associated with the changes of
defecation habit, such as constipation and/or diarrhea. Clinical treatment of IBS includes
behavioral, and drug treatment, such as anti-diarrheal agent, 5-HT3 receptor antagonist and
5-HT4 receptor agonist, but these treatments relieve partial symptoms only.
Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) origins from Yizongjinjion, and that uses XSLJZT to treat
the patients who has qi deficiency, phlegm-retained fluid, nausea and vomiting,
gastrointestinal dysharmony and producing many symptoms. These symptoms of mentioned-above
are similar to IBS. Therefore, the purpose of the present study was to investigate the
therapeutic effect of XSLJZT on IBS, the investigators designed a randomized double blind
placebo control study to assess the effect of XSLJZT on IBS.